Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Antibiotic resistance among urinary tract pathogens (CROSBI ID 95210)

Prilog u časopisu | pregledni rad (znanstveni) | međunarodna recenzija

Tambić-Andrašević, Arjana ; Andrašević, Saša ; Škerk, Višnja Antibiotic resistance among urinary tract pathogens // International journal of antimicrobial agents, 17 (2001), S1; S91,-No P20002

Podaci o odgovornosti

Tambić-Andrašević, Arjana ; Andrašević, Saša ; Škerk, Višnja

engleski

Antibiotic resistance among urinary tract pathogens

Urinary tract infections (UTI) are often treated empirically and the aim of this study was to investigate the incidence of resistance among bacteria causing UTI. We analysed prospectively 101 adult patients (age 15-92) who were admitted to our hospital for acute urinary tract infection. Antibiotic sensitivity testing was done by disk diffusion method. Twenty-eight patients (28%) presented with acute uncomplicated pyelonephritis and in all of them the causative agent was Escherichia coli with sensitivity to antibiotics as follows, co-trimoxazole 90%, ampicilin 65%, co-amoxiclav 90%, and cefalexin, cefuroxime, ceftazidim, gentamicin, netilmicin, amikacin, nitrofurantoin, norfloxacin, and ciprofloxacin 100%. In 72 patients UTI was considered to be recurrent, complicated or both. In these patients predominant isolate was still E.coli (83%), followed by Klebsiella spp. (5%). Bacterial isolates from patients with recurrent uncomplicated UTI showed similar sensitivity to antibiotics as those causing primary uncomplicated pyelonephritis. Bacteria causing complicated UTI showed lower sensitivity to antibiotics, co-trimoxazole 77%, ampicillin 50%, co-amoxiclav 84%, cefalexin 77%, cefuroxime 84%, ceftazidim 89%, gentamicin 77%, netilmicin 91%, amikacin 86%, nitrofurantoin 80%, norfloxacin 86%, and ciprofloxacin 98%. Empiric therapy should be carefully chosen according to the local antibiotic resistance surveillance data and clinical features of individual patient.

NA

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

17 (S1)

2001.

S91,-No P20002

objavljeno

0924-8579

Povezanost rada

Kliničke medicinske znanosti